- Home
- MYNZ vs GLTO Comparison
MYNZ vs GLTO Comparison
Compare MYNZ & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYNZ
- GLTO
- Stock Information
- Founded
- MYNZ 2021
- GLTO 2011
- Country
- MYNZ Germany
- GLTO Denmark
- Employees
- MYNZ N/A
- GLTO N/A
- Industry
- MYNZ Biotechnology: Pharmaceutical Preparations
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- MYNZ Health Care
- GLTO Health Care
- Exchange
- MYNZ Nasdaq
- GLTO Nasdaq
- Market Cap
- MYNZ 7.6M
- GLTO 4.5M
- IPO Year
- MYNZ 2021
- GLTO 2020
- Fundamental
- Price
- MYNZ $1.90
- GLTO $3.28
- Analyst Decision
- MYNZ Buy
- GLTO Buy
- Analyst Count
- MYNZ 2
- GLTO 1
- Target Price
- MYNZ $14.00
- GLTO $10.00
- AVG Volume (30 Days)
- MYNZ 186.6K
- GLTO 25.6K
- Earning Date
- MYNZ 08-05-2025
- GLTO 08-11-2025
- Dividend Yield
- MYNZ N/A
- GLTO N/A
- EPS Growth
- MYNZ N/A
- GLTO N/A
- EPS
- MYNZ N/A
- GLTO N/A
- Revenue
- MYNZ $893,991.00
- GLTO N/A
- Revenue This Year
- MYNZ $26.06
- GLTO N/A
- Revenue Next Year
- MYNZ $4.97
- GLTO N/A
- P/E Ratio
- MYNZ N/A
- GLTO N/A
- Revenue Growth
- MYNZ N/A
- GLTO N/A
- 52 Week Low
- MYNZ $1.34
- GLTO $2.01
- 52 Week High
- MYNZ $19.00
- GLTO $15.13
- Technical
- Relative Strength Index (RSI)
- MYNZ 49.46
- GLTO 51.86
- Support Level
- MYNZ $1.89
- GLTO $3.40
- Resistance Level
- MYNZ $2.07
- GLTO $3.94
- Average True Range (ATR)
- MYNZ 0.21
- GLTO 0.34
- MACD
- MYNZ 0.02
- GLTO -0.00
- Stochastic Oscillator
- MYNZ 38.10
- GLTO 39.00
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.